Kinmen Group: Montmorillonite powder has been approved for listing, with a total research and development investment of 3.6085 million yuan.

Jianmin Group announced that the company has received the "Drug Registration Certificate" issued by the National Medical Products Administration, and the developed montmorillonite powder has been approved for listing. The approval number is valid until June 29, 2031. This drug is used for acute and chronic diarrhea in adults and children, and has the same active ingredients as the original reference preparation. As of June 30, 2026, the accumulated research and development expenses is approximately 3.6085 million yuan. The approval for listing will enrich the product line, but it is not expected to have a significant impact on performance in the short term, and there is uncertainty in market share.